Please login to the form below

Not currently logged in
Email:
Password:

Plavix generics weigh heavy on BMS in second quarter

Net sales down 18 per cent

As expected, generic competition to top-selling antiplatelet drug Plavix and other key products dragged down revenues and profits at Bristol-Myers Squibb (BMS) in the second quarter.

The pharma company reported net sales down 18 per cent to $4.4bn, thanks to the loss of patent protection for Plavix (clopidogrel) and blood pressure drugs Avapro (irbesartan) and Avalide (irbesartan/hydrochlorothiazide) in the US since the start of the year, while net income fell 29 per cent to $645m.

As a result, the company cut its 2012 earnings forecasts from $1.90-$2.00 per share to $1.78-$1.88.

Chief executive Lambert Andreotti put a positive spin on the figures, noting that if these products are excluded, growth year-on-year for the rest of the firm's portfolio was a healthy 8 per cent.

"We have been preparing for the expected loss of exclusivity of Plavix and Avapro/Avalide for a number of years," he said, noting that BMS' $7bn purchase of diabetes specialist Amylin and expansion of its collaboration with AstraZeneca would help the company recover.

Plavix sales plummeted 60 per cent to $741m from nearly $1.9bn a year ago, with Avapro/Avalide falling 53 per cent to $117m, while schizophrenia and bipolar depression treatment Abilify (aripiprazole) managed a modest 1 per cent gain to $711m.

On a brighter note, most of BMS' other key products posted solid gains. Hepatitis treatment Baraclude (entecavir) grew 22 per cent to $357m in the quarter, while HIV drugs Reyataz (atazanavir) and Sustiva (efavirenz) rose 3 per cent to $406m and 5 per cent to $388m, respectively.

A crop of more recently-launched products also showed strong gains, with Yervoy (ipilimumab) for melanoma advancing 71 per cent to $162m, prostate cancer drug Sprycel (dasatinib) coming in at $244m, up 26 per cent, while arthritis treatment Orencia (abatacept) rose 27 per cent to $290m.

Meanwhile, diabetes drugs Onglyza (saxagliptin) and Kombiglyze (saxagliptin/metformin) grew 54 per cent to $172m, and Andreotti said the new Amylin/AZ deal will help drive sales of this franchise alongside Amylin's GLP-1 products Byetta (exenatide) and long-acting follow-up Bydureon.

Turning to the pipeline, Andreotti noted that BMS is waiting for an EU verdict on another diabetes treatment - Forxiga (dapagliflozin) - in the second half of the year, and now has a "clear path forward" to bring Eliquis (apixaban) for the prevention of stroke and systemic embolism in patients with atrial fibrillation after receiving a complete response letter from the US Food and Drug Administration (FDA).

Andreotti also commented that BMS intends to start phase III trials of its cancer immunotherapy PD-1 in lung and kidney cancer within the next few months, with pivotal trials in melanoma due around the turn of the year.

"On balance, our second quarter performance sets a good foundation for the future of our company," he said.

26th July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Digital Healthcare Agency

Random42 is the world's premier medical animation company. Over the past 20 years we have created over 350 mechanism-of-action (MoA)...

Latest intelligence

When forecasters take the floor: 6 tips on presenting a forecast
Peter Mansell queries some of pharma’s leading forecasters for their dos and don’ts on presenting a forecast...
Enablers of drug innovation could lie in the numbers
Christopher Ehinger of Black Swan Analysis addresses the problem of clinical-trial recruitment as a barrier to new drug development and offers a new way of looking at the problem....
Forecasting for Licensed Compounds
Peter Mansell examines the impact of heavier in-licensing/out-licensing traffic on pharmaceutical forecasting...

Infographics